Senseonics Holdings, Inc.
SENSHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Senseonics Holdings, Inc. focuses on Medical Devices services and products. Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the. Valued at $397.1M, SENS is a small-cap name in its sector. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Market Cap
$397.1M
Beta
1.03
P/E (TTM)
—
P/E (Fwd)
-3.84
EPS (TTM)
$-2.26
EPS (Fwd)
$-1.95
ROE
-118.2%
ROA
-41.4%
Cash
$142.7M
Total Debt
$62.8M
Free CF
-$59.2M
52W Change
7.1%
Annual Financials
Cash vs Debt
Where SENS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SENS finished 12.64% above its 150-day moving average ($7.12) and 12.48% above its 200-day moving average ($7.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SENS overbought or oversold?
At the October 20, 2026 close, SENS's RSI(14) was 26.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $142.7M in cash comfortably exceeding the $62.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$59.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -118.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $16.4M (2022) to $35.3M (2025), reflecting a 115% increase over the period.
With cash comfortably exceeding debt, SENS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Senseonics Holdings, Inc. and its sector.